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Edited by Ulrike KutayAbstract Shortage of oxygen is one of the prime stress condi-
tions in tissues. In this study, we looked for microRNAs ex-
pressed during hypoxia and showed that miR-210 expression
was upregulated in response to hypoxia in vitro and in vivo. An
active form of the HIF-1a induced the expression of miR-210,
showing the involvement of the HIF-1 signaling pathway in
miR-210 gene transcription. Furthermore, miR-210 was shown
to bind to the predicted target sites of ephrin-A3 or neuronal
pentraxin 1, causing repression in luciferase reporter activity.
Contrary to the microRNA-mediated repression hypothesis, eph-
rin-A3 was expressed at very high levels in post-ischemic mouse
hippocampus in vivo. Thus, the regulatory eﬀects of miR-210 on
its targets in vivo need to be further characterized.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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pentraxin 11. Introduction
Hypoxia is one of the prime stress conditions in tissues and it
is important in the pathogenesis of several human diseases, such
as heart disease, stroke, diabetes and cancer. Cells adapt to hy-
poxia by both transcriptional and translational regulation. Hy-
poxia-responsive transcription factors (TFs) are activated by
oxygen sensing protein hydroxylases. A major member of the
hypoxia-responsive TFs are the hypoxia-inducible factors
(HIFs) which activate hundreds of genes in a cell-type speciﬁc
way [1]. In response to low oxygen level, protein translation is
globally inhibited [2] by the suppression of multiple key regula-
tors of translation needed in ribosome binding or translation
elongation [3]. However, there are several hypoxia-responsive
genes, which translate more eﬃciently during oxygen depriva-
tion [4]. Little is known about the possible changes in the expres-
sion of non-coding genes or structural changes in the chromatin
during hypoxia.*Corresponding author. Present address: Department of Biotechnol-
ogy and Molecular Medicine, A. I. Virtanen Institute, University of
Kuopio, P.O. Box 1627, FIN-70211 Kuopio, Finland. Fax: +358 17
163751.
E-mail address: seppo.ylaherttuala@uku.ﬁ (S. Yla¨-Herttuala).
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doi:10.1016/j.febslet.2008.05.048In this study,we investigated a possible role formicroRNAs in
the signaling cascades induced by oxygen deprivation in cells.
MicroRNAs are 18–22 nucleotides RNAs in lenght and regulate
gene expression at the mRNA level. The expression of target
proteins is regulated through imperfect base pairing with 3 0
untranslated regions (UTRs) of mRNAs.MicroRNA-mediated
gene regulation functions via the inhibition of protein transla-
tion [5] or the promotion of mRNAdecay [6]. However, transla-
tional inhibition bymicroRNAs is reversible andmRNAs canbe
released to translation [7]. Vasudevan et al. [8] recently showed
that in response to environmental stress, microRNAs can also
enhance the translation of target proteins. MicroRNA-medi-
ated regulation of protein expression is a complex process. It is
dependent on the 3 0UTR regions of the mRNA, and more spe-
ciﬁcally, interactions with diﬀerent RNA binding proteins [7].2. Materials and methods
2.1. Cell culture
Umbilical cords for the isolation of human vein endothelial cells
(HUVECs) were collected at the Kuopio University hospital conform-
ing to regulations outlined in the Declaration of Helsinki (Cardiovas-
cular Research 1997;35:2–3). HUVECs were isolated by collagenase
(0.3 mg/ml) digestion and the remaining erythrocytes were removed
with BD Pharm Lyse (BD Biosciences). Cells were cultured (37 C,
5% CO2) in EBM medium containing EGM Bulletkit (Clonetics) in
ﬁbronectin/gelatin coated ﬂasks. For microRNA proﬁling, isolated
cells from three umbilical cords were combined. 24 h before treatment,
the medium was changed to basal medium (0.5% FBS and 100 U/ml
penicillin -streptomycin in EBM). Cells treated with hypoxia were ex-
posed to a steady ﬂow of low-oxygen gas mixture (1% O2, 5% CO2,
94% N2) in a modular incubator chamber (Billups-Rothenberg, CA)
for 24 h. Chemical hypoxia was obtained with 100 lM deferoxamine
mesylate (DFM, #D-5933, Sigma) in EBM medium. 293T, HeLa,
MRC-5 and Jurkat cells were cultured in supplemented DMEM
(10% FBS and 100 U/ml penicillin–streptomycin, Gibco). Hypoxia
treatment was performed as with HUVECs.2.2. RNA extraction, cloning of microRNAs and real-time quantitative
PCR
RNA was isolated with TRIzol reagent (Invitrogen). MicroRNAs
were cloned as described earlier [9]. For quantitative RT-PCR,
microRNAs were reverse transcribed into cDNAs with a Taqman
MicroRNA Reverse Transcription Kit and microRNA speciﬁc primers
from Taqman MicroRNA Assays (Human Panel-Early Access Kit,
Applied Biosystems). cDNAs were ampliﬁed by RT-PCR with real-
time detection. The data were normalized with 18S rRNA.blished by Elsevier B.V. All rights reserved.
Table 1
Cloned microRNAs from hypoxic HUVECs
microRNAs Frequency
miR-21 14
miR-143 7
let-7b 4
miR-104 3
miR-126 3
miR-130a 3
miR-23b 2
miR-125a 2
miR-125b 2
miR-16 1
miR-23 1
miR-103 1
miR-145 1
miR-204 1
let-7c 1
let-7f 1
miR-24 1
miR-126* 1
miR-161 1
total 51
Table 2
MicroRNAs with DCt > ±1 in hypoxia vs. control in HUVECs
Hypoxia DFM
miR-210 2.10 2.69
miR-181b 1.91 1.09
miR-148a 1.84 1.70
miR-23b 1.81 0.84
miR-216 +1.79 +0.67
miR-26b 1.77 2.15
miR-9 +1.63 +0.27
miR-16 1.42 1.17
miR-125a 1.39 1.18
miR-128a 1.35 1.06
miR-20 1.33 1.36
miR-214 1.26 1.00
miR-299 1.25 1.05
miR-155 1.24 1.97
miR-199a 1.20 1.96
miR-30c 1.20 1.10
miR-30a-3p 1.17 0.93
let-7e 1.15 1.46
miR-213 1.15 0.81
miR-342 1.14 0.71
miR-150 1.13 0.85
miR-335 1.12 +0.09
miR-185 1.10 0.32
miR-137 1.08 0.72
miR-30b 1.08 1.00
let-7b 1.04 0.34
miR-204 1.04 0.76
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An oligonucleotide duplex containing the predicted binding site of
miR-210 present in the 3 0UTR of ephrin-A3 (EFNA3-forward:
5 0-CTAGACAGGACCTATGCAACGCACAGT-3 0; EFNA3-reverse:
5 0-CTAGACTGTGCGTTGCATAGGTCCTGT-3 0) or neuronal
pentraxin 1 (NPTX1-forward: 5 0-CTAGTCGCCCCTGCACACGCA-
CAC-3 0, NPTX1-reverse: 5 0-CTAGGTGTCCGTGTGCAGGGGC-
GA-3 0) was inserted in triplicate after the luciferase gene (pGL3-
Control vector, Promega). The plasmids were cotransfected with pre-
miR-210 or pre-miR negative control oligonucleotides into 293T cells
following manufacturers protocols (pre-miR miRNA precursor mole-
cules and NeoFX Transfection Reagent, Ambion). Luciferase activity
was measured 24 h after transfection with the Promega Luciferase as-
say.
2.4. Mouse hind limb ischemia model
Unilateral hind limb ischemia was induced in C57Bl/6 mice by ligat-
ing the left femoral artery proximal to the bifurcation of the saphenous
and popliteal arteries [10]. Animals were sacriﬁced 3 or 7 days after the
operation and muscle samples snap frozen with liquid nitrogen for
RNA isolation.
2.5. HIF-1a transduction of rabbit hind limb muscle
An adenovirus expressing a stabilized form of HIF-1a was delivered
into the rabbit hind limb skeletal muscle using intramuscular injections
containing a total amount of 1011 virus particles [11]. Six days after
gene transfer, animals were sacriﬁced and muscle samples were snap
frozen for RNA isolation.
2.6. Induction of cerebral ischemia
Cerebral ischemia was produced by inserting a nylon thread through
the common carotic artery into the posterior carotid artery (PCA) of
C57Bl/6 mice [12]. After 60 min of ischemia, the PCA blood ﬂow
was restored by removing the thread. Three days post-ischemia the ani-
mals were sacriﬁced and perfused with heparinized saline. For immu-
nohistochemistry, the brains were immersion-ﬁxed with 4% PFA for
24 h and cryoprotected in 30% sucrose for 3 days. Frozen brains were
cut into 20 lm-thick cryosections.
2.7. Animals
All animal experiments were carried out according to the National
Institute of Health (NIH) guidelines for the care and use of laboratory
animals, and approved by the Ethical Committee of the National Lab-
oratory Animal Center, University of Kuopio, Finland. All animals
were kept in a light and temperature controlled environment with ad
libitum food and water.
2.8. Immunohistochemistry
Immunodetection of ephrin-A3 was achieved with an ephrin-A3
antibody (Ab) (sc-20720, Santa Cruz) and Tyramide ﬂuorophore
ampliﬁcation kit, according to instructions provided by the manufac-
turer (TSA Plus Cyanine 3 Kit, NEL-744001, Perkin–Elmer). In brief,
tissue slides were incubated in 0.3% H2O2/PBS for 5 min, followed by
blocking solution for 30 min. Primary Ab (1:1000) binding was over-
night followed by 3 · 5 min PBS washes and a secondary Ab incuba-
tion for 30 min. The TSA-ﬂuorophore (1:100) incubation time was
5 min. Slides were mounted with Vectashield mounting medium
containing DAPI (Vector laboratories) and photographs were taken
and processed using an Olympus AX70 microscope (Olympus Optical,
Japan).3. Results and discussion
3.1. Hypoxia induces miR-210 in normal cells and in cancer cell
lines
The results of microRNA cloning from hypoxic HUVECs
are shown in Table 1. We then quantiﬁed the expression of
miR-21, -143, let-7b, miR-104, -126, -130a, -23b, -125a, -
125b, -16, -23, -103, -145 and -204 together with 138 additional
microRNAs both in control HUVECs and in hypoxic or DFM
treated HUVECs with real-time quantitative PCR. When com-paring the expression of these 152 microRNAs in hypoxic and
control cells, 30 microRNAs had DCt > ±1 (Table 2). MicroR-
NA miR-210 showed expression diﬀerence DCt > 2, and was
chosen into further characterization. Signiﬁcantly diﬀerent lev-
els of expression in hypoxia and DFM treated HUVECs were
seen (4.5- and 9.6-fold increase compared to control cells,
respectively, Fig. 1A). Upregulation of miR-210 by hypoxia
and DFM was additionally tested in four other cell lines
(293T, HeLa, Jurkat, MRC-5) with similar results. Our results
are consistent with the study published by Kulshreshtha and
colleagues [13], were they showed hypoxia induced expression
of miR-210 in diﬀerent cancer cell lines. According to the miR-
base [14], the sequence of mature miR-210 is highly conserved
Fig. 1. MiR-210 expression in hypoxic cell lines (A) and 3 or 7 days post-ischemic mouse or HIF-1a-transduced rabbit hind limb muscles (B). The
expression of miR-210 was measured with real-time PCR and normalized with 18S rRNA and compared to non-treated cells (A) or intact muscle
from the same animal (B) to calculate the fold change in miR-210 expression (means ± S.E.M.). (A) C control, H hypoxia with low-oxygen gas, D
DFM-induced hypoxia. A clear upregulation of miR-210 was seen in all cell lines treated with DFM (9.6 ± 2.6, n = 3 in HUVEC, 6.64 in 293T, 5.59
in HeLa, 9.93 in MRC-5, 8.04 in Jurkat). All cell lines, except Jurkat, responded to low-oxygen treatment with an upregulation of miR-210 (4.5 ± 0.9,
n = 3 in HUVEC, 3.35 in 293T, 2.98 in HeLa, 3.12 in MRC-5, 0.71 in Jurkat). (B) MiR-210 was upregulated, 3 days post-ischemia (3.36 ± 0.70, n = 7)
and with AdHIF-1a (5.29 ± 1.90, n = 3). MiR-210 was not upregulated 7 days post-ischemia (0.67 ± 0.12, n = 8).
Fig. 2. M-210 is predicted to bind to the target sequence in ephrin-A3
or neuronal pentraxin 1 3 0UTRs. (A) Predicted base pairing of miR-
210 to the 3 0UTR of ephrin-A3 (EFNA3) or neuronal pentraxin 1
(NPTX1) mRNA. (B) Relative luciferase reporter activity when
ephrin-A3 or neuronal pentraxin 1 3 0UTR binding sites for miR-210
(pGL3-EFNA3 and pGL3-NPTX1) were transiently co-transfected
with pre-miR-210 or pre-miR-control (pre-miR-ctrl) in 293T cells.
Luciferase activity was normalized to total protein amount and the
error bars represent S.E.M. from three independent experiments.
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miR-210 is located in an intergenic region and is most proba-
bly transcribed as an independent gene.
As gene regulators under hypoxic conditions, microRNAs
have some advantages compared to protein-coding genes.
Firstly, they do not need translational machinery, which is
inhibited during low oxygen [2]. Secondly, since microRNAs
regulate protein synthesis of existing mRNAs, the eﬀect on
protein level is faster than regulating target genes at transcrip-
tional level.
3.2. Hypoxia and HIF-1a activate miR-210 expression in vivo
Hypoxic induction of miR-210 was tested in vivo in ischemic
mouse hind limb muscles (Fig. 1B). A clear upregulation in
miR-210 expression (3.4-fold change compared to intact mus-
cle) was detected in ischemic muscles 3 days after artery liga-
tion. The expression of miR-210 returned to normal 7 days
after the operation. MiR-210 levels were also upregulated in
muscles transduced with a constitutively active form of Ad-
HIF-1a (Fig. 1B), suggesting that miR-210 induction is acti-
vated by HIF-1a. Recently, Camps et al. [15] showed miR-
210 upregulation in breast cancer in vivo and HIF-1a/VHL
mediated induction of miR-210 in renal cancer cell line. We
have now shown that the induction of miR-210 expression is
a normal response to hypoxia also in primary cells and in nor-
mal tissues, and is not necessarily related to cancerous cell-
type.
3.3. Binding of miR-210 to ephrin-A3 and neuronal pentraxin 1
mRNAs
We used three diﬀerent prediction algorithms: miRanda [16],
TargetScan [17] and PicTar [18] in order to ﬁnd possible tar-
gets for miR-210. The algorithms gave two common targets:
ephrin-A3 (EFNA3) and neuronal pentraxin 1 (NPTX1). We
inserted the miR-210 binding site sequence from the 3 0UTR
of ephrin-A3 or neuronal pentraxin 1 mRNA (Fig. 2A) into
the 3 0UTR of the luciferase gene, as three consecutive se-
quences. The presence of the ephrin-A3 binding site reduced
luciferase expression to 45% in the presence of pre-miR-210
compared to the pre-miR-ctrl (Fig. 2B). Similarly, the binding
site sequence from the 3 0UTR of neuronal pentraxin 1 mRNAreduced luciferase expression to 52% in the presence of pre-
miR-210 compared to the pre-miR-ctrl (Fig. 2B).
3.4. Expression of ephrin-A3 and neuronal pentraxin 1 in
ischemic brain
Ephrin-A3 is a GPI-anchored membrane protein [19] and is
expressed in human adult brain and skin [20]. In the brain, the
glial ephrin-A3 and the neuronal EphA4 ligand–receptor inter-
action regulates the post-synaptic morphology of neurons [21].
During development, ephrin-A3 has a role in neuronal axon
2400 K. Pulkkinen et al. / FEBS Letters 582 (2008) 2397–2401guidance by inhibiting the growth of neurites [22,23]. Neuronal
pentraxin 1 is also expressed in the brain, exclusively by neurons
[24]. It is a secreted glycoprotein that mediates hypoxic injuries
in primary cortical neurons after their exposure to hypoxia [25].
Since both of these target proteins for miR-210 are speciﬁ-
cally expressed in the brain, and the expression of neuronal
pentraxin 1 in ischemic brain has been shown [25], we studied
the expression of the ephrin-A3 protein in ischemic mouse
brain. A clear upregulation of ephrin-A3 was seen in the hip-
pocampus of the ischemic hemisphere compared to the contra-
lateral control. The pyramidal layers in areas CA1 and CA3,
and the granular layer in dentate gyrus showed a strong ische-
mia-induced expression of ephrin-A3, compared to the control
hemisphere where expression was low (Fig. 3A and B). ThereFig. 3. The expression of ephrin-A3 3 days after hypoxic-ischemic injury i
immunoﬂuorescence using an anti-ephrin-A3 polyclonal antibody and a
hippocampal expression of ephrin-A3 under hypoxia, compared to the contr
hippocampus are roundshaped and ephrin-A3 expression is prominent in th
ephrin-A3 is only modestly expressed and exhibits a diﬀerent expression patte
500 lm for A, B, E and F, and 100 lm for C and D.was some expression in the control side of the hippocampus
in the pyramidal layer of CA3 (Fig. 3D), but the expression
was clearly diﬀerent from that seen in ischemic side (Fig. 3C).
If microRNAs mediate gene regulation by repressing their
targets, our results showing hypoxia-inducible miR-210
expression and enhanced ephrin-A3 protein expression in
ischemia are apparently contradictory. However, since there
is evidence for microRNAs to upregulate the translation of
their targets under stress conditions [8], it is possible that
miR-210 operates as a translational enhancer in hypoxic con-
ditions in vivo. The ischemia induced events in brain are very
complex and further studies are still needed to clarify the exact
mechanism of the eﬀects of miR-210 on the expression of eph-
rin-A3 and neuronal pentraxin 1.n the adult mouse brain. Frontal sections (20 lm) were subjected to
ﬂuorescent secondary antibody. (A) Intensive red staining shows
alateral hemisphere of the brain (B). (C) Neurons in CA3 layer of the
e neuronal layer. (D) In comparison, in the control side of the brain,
rn. Sections were counterstained with DAPI (E and F). The scale bar is
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